Last Updated on October 17, 2024 by The Health Master
New Delhi: The US health regulator has asked drug major Dr Reddy’s Laboratories to initiate voluntary action at its Duvvada facility in Andhra Pradesh.
“With regard to the audit of our Formulations Manufacturing Plant at Duvvada, Visakhapatnam, we would like to inform you,
That we have been notified by the United States Food and Drug Administration (USFDA), that the inspection classification of the above-referred facility is determined as Voluntary Action Initiated,” Dr Reddy’s Laboratories said in a BSE filing.
Shares of Dr Reddy’s Laboratories closed at Rs 3,307.50 apiece, down 0.55 per cent on the BSE.
Also read: Dr. Reddy’s Lab to acquire 62 brands of Wockhardt
